Unravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment options

The discovery of activating epidermal growth factor receptor (EGFR) mutations has opened up a new era in the development of more effective treatments for patients with non-small cell lung cancer (NSCLC). However, patients with EGFR-activating mutated NSCLC treated with EGFR tyrosine kinase inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Remon, Jordi, Besse, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070255/
https://www.ncbi.nlm.nih.gov/pubmed/27843631
http://dx.doi.org/10.1136/esmoopen-2016-000081

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070255/
https://www.ncbi.nlm.nih.gov/pubmed/27843631
http://dx.doi.org/10.1136/esmoopen-2016-000081

Ejemplares similares